The company's natural production platform has the potential to treat public health problems, rare conditions, long-term diseases, and global pandemic threats. SAB Biotherapeutics develops fully human antibodies produced from transchromosomic (Tc) bovine herds that target specific diseases, including COVID-19, influenza, type 1 diabetes, and cancer, without the need for human donors.